US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Lunai Bioworks

0.4800

-0.0654-11.99%

Volume:243.81K

Turnover:122.78K

Market Cap:11.61M

PE:-0.06

High:0.5800

Open:0.5550

Low:0.4610

Close:0.5454

52wk High:14.00

52wk Low:0.4610

Shares:24.19M

Float Shares:14.71M

Volume Ratio:0.77

T/O Rate:1.66%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-7.5469

EPS(LYR):-10.7843

ROE:-366.44%

ROA:-13.32%

PB:-0.86

PE(LYR):-0.04

Loading ...

Overview Company News Filings

Nasdaq Moves to Delist Lunai Bioworks Securities

Lunai Bioworks Secures U.S. Patent for AI Debiasing Framework in Drug Discovery

Lunai Bioworks Inc. - Common Stock Q2 EPS $(0.08) Up From $(0.45) YoY

Lunai Bioworks net income loss narrows to USD 1.80 million in Q4, down 75 percent

Lunai Bioworks CEO Showcases AI Drug Discovery Platform on CNBC

Nasdaq Moves to Delist Lunai Bioworks for Minimum Bid Price Violation

Lunai Bioworks Unveils AI Platform Targeting Disease Subtypes for Precision Drug Discovery

Lunai Bioworks startet KI-Onkologie-Pilotprojekt mit klinischem Partner

Lunai Bioworks (Nasdaq: Lnai) Launches AI Oncology Pilot With Clinical-Stage Partner to Analyze Randomized Phase 2 Metastatic Colorectal Cancer Survival Trial Data

THOMSON REUTERS

Lunai Bioworks Unveils AI Tool to Block Novel Chemical Weapon Designs

Lunai Bioworks Secures NIH Grant for Alcohol Use Disorder Drug Discovery Program

Lunai Bioworks Unveils AI-Driven Platform to De-Risk Drug Discovery in Complex Diseases

Lunai Bioworks Inc - Identifies Three Parkinson's Disease Subtypes

THOMSON REUTERS

Lunai Bioworks Inc - Prioritized Drug Targets in $13 Bln Parkinson's Market

THOMSON REUTERS

Lunai Bioworks Identifies Three Parkinson's Subtypes and Prioritizes Drug Targets

BRIEF-Lunai Bioworks - Enters Sales Agreement With Dawson James Securities - SEC Filing

Lunai Bioworks Inc - May Offer & Sell Stock up to $11.70 Mln - SEC Filing

THOMSON REUTERS

Lunai Bioworks Raises $3.1 Million in Private Placement of Shares and Warrants

Lunai Bioworks Secures First Licensing LOI for Immune Cell Therapy

Lunai Bioworks Secures First Licensing Loi Following Landmark Breakthrough Showing Complete Tumor Regression in Humanized Cancer Models

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/LNAI/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"LNAI","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LNAI\",,,,,undefined,":{"symbol":"LNAI","market":"US","secType":"STK","nameCN":"Lunai Bioworks","latestPrice":0.48,"timestamp":1771880400000,"preClose":0.5454,"halted":0,"volume":243806,"delay":0,"changeRate":-0.11991199119911994,"floatShares":14705800,"shares":24187399,"eps":-7.5469,"marketStatus":"Pre-Mkt","change":-0.0654,"latestTime":"02-24 04:55:52 EST","open":0.555,"high":0.58,"low":0.461,"amount":122780.6772194,"amplitude":0.218188,"askPrice":0.768,"askSize":200,"bidPrice":0.4185,"bidSize":100,"shortable":0,"etf":0,"ttmEps":-7.5469,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1771943400000},"marketStatusCode":1,"adr":0,"exchange":"NASDAQ","adjPreClose":0.48,"postHourTrading":{"tag":"盘后","latestPrice":0.472,"preClose":0.48,"latestTime":"19:57 EST","volume":2093,"amount":995.3879,"timestamp":1771894642172,"change":-0.008,"changeRate":-0.016667,"amplitude":0.040833},"volumeRatio":0.7651440312964782,"impliedVol":1.4337,"impliedVolPercentile":0.7629},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LNAI\",,,,,undefined,":{"symbol":"LNAI","floatShares":14705800,"roa":"-13.32%","roe":"-366.44%","lyrEps":-10.784282,"volumeRatio":0.7651440312964782,"shares":24187399,"dividePrice":0,"high":0.58,"amplitude":0.218188,"preClose":0.5454,"low":0.461,"week52Low":0.461,"pbRate":"-0.86","week52High":14,"institutionHeld":0,"latestPrice":0.48,"committee":-0.333333,"eps":-7.5469,"divideRate":0,"volume":243806,"delay":0,"ttmEps":-7.5469,"open":0.555,"prevYearClose":0.8817,"prevWeekClose":0.5454,"prevMonthClose":0.7804,"prevQuarterClose":0.8817,"fiveDayClose":0.7344,"twentyDayClose":0.878,"sixtyDayClose":1.27},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/LNAI\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-02-17","symbol":"LNAI","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1771304400000,"reportTimeType":"","actualEps":null},{"market":"US","date":"2025-11-14","symbol":"LNAI","fiscalQuarterEnding":"2025/09","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1763096400000,"reportTimeType":"post","actualEps":0.13},{"market":"US","date":"2025-09-30","symbol":"LNAI","defaultRemindTime":1759239000000,"type":"split","dateTimestamp":1759204800000,"forFactor":10,"toFactor":1,"ratio":10},{"market":"US","date":"2025-09-29","symbol":"LNAI","fiscalQuarterEnding":"2025/06","expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1759118400000,"reportTimeType":"","actualEps":-0.76},{"market":"US","date":"2025-05-15","symbol":"LNAI","fiscalQuarterEnding":"2025/03","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1747281600000,"reportTimeType":"post","actualEps":0}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"LNAI\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"LNAI\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/LNAI\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"LNAI","date":"2026-02-23","current":-0.063602,"percent":1,"low":-0.265446,"twenty":-0.18891,"median":-0.160823,"eighty":-0.133334,"high":-0.105094,"avg":-0.163321,"sd":0.035518,"marketCap":13191783},"quantilePoints":[{"date":"2025-10-03","current":-0.160171,"twenty":-0.164877,"median":-0.163112,"eighty":-0.161348,"marketCap":28511703},{"date":"2025-10-10","current":-0.161474,"twenty":-0.165919,"median":-0.164078,"eighty":-0.161474,"marketCap":28743506},{"date":"2025-10-17","current":-0.158869,"twenty":-0.16512,"median":-0.161474,"eighty":-0.158869,"marketCap":28279901},{"date":"2025-10-24","current":-0.135429,"twenty":-0.16512,"median":-0.160171,"eighty":-0.152098,"marketCap":24107456},{"date":"2025-10-31","current":-0.122514,"twenty":-0.163557,"median":-0.158218,"eighty":-0.135687,"marketCap":21808324},{"date":"2025-11-07","current":-0.132813,"twenty":-0.161474,"median":-0.152344,"eighty":-0.130739,"marketCap":23641716},{"date":"2025-11-14","current":-0.134115,"twenty":-0.161474,"median":-0.143888,"eighty":-0.121701,"marketCap":23873497},{"date":"2025-11-21","current":-0.254829,"twenty":-0.163557,"median":-0.147149,"eighty":-0.123011,"marketCap":33376540},{"date":"2025-11-28","current":-0.211108,"twenty":-0.166054,"median":-0.152344,"eighty":-0.125001,"marketCap":27650221},{"date":"2025-12-05","current":-0.232577,"twenty":-0.211108,"median":-0.158218,"eighty":-0.130221,"marketCap":30462108},{"date":"2025-12-12","current":-0.20753,"twenty":-0.221843,"median":-0.160171,"eighty":-0.132813,"marketCap":27181573},{"date":"2025-12-19","current":-0.184259,"twenty":-0.212897,"median":-0.161474,"eighty":-0.134115,"marketCap":24133572},{"date":"2025-12-26","current":-0.176388,"twenty":-0.211466,"median":-0.164729,"eighty":-0.134115,"marketCap":23102623},{"date":"2026-01-02","current":-0.157729,"twenty":-0.211108,"median":-0.164729,"eighty":-0.134896,"marketCap":20658806},{"date":"2026-01-09","current":-0.162828,"twenty":-0.208961,"median":-0.16538,"eighty":-0.135424,"marketCap":21326580},{"date":"2026-01-16","current":-0.16442,"twenty":-0.206179,"median":-0.165717,"eighty":-0.136203,"marketCap":21535113},{"date":"2026-01-23","current":-0.164223,"twenty":-0.200455,"median":-0.16538,"eighty":-0.13724,"marketCap":21509339},{"date":"2026-01-30","current":-0.150287,"twenty":-0.192502,"median":-0.16442,"eighty":-0.139063,"marketCap":19684091},{"date":"2026-02-06","current":-0.115725,"twenty":-0.190708,"median":-0.163453,"eighty":-0.135462,"marketCap":15157289},{"date":"2026-02-13","current":-0.146316,"twenty":-0.189626,"median":-0.161474,"eighty":-0.135462,"marketCap":19163931},{"date":"2026-02-20","current":-0.111222,"twenty":-0.189268,"median":-0.161474,"eighty":-0.134115,"marketCap":13960941},{"date":"2026-02-23","current":-0.105094,"twenty":-0.18891,"median":-0.160823,"eighty":-0.133334,"marketCap":13191783}],"updateTime":1771926952547},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"LNAI\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2613260730","title":"Nasdaq Moves to Delist Lunai Bioworks Securities","url":"https://stock-news.laohu8.com/highlight/detail?id=2613260730","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613260730?lang=en_us&edition=fundamental","pubTime":"2026-02-24 05:33","pubTimestamp":1771882434,"startTime":"0","endTime":"0","summary":"Lunai Bioworks Inc. said it received a notice from Nasdaq’s Listing Qualifications Staff determining that the company’s securities should be delisted. The company has appealed and secured a Nasdaq Hearings Panel hearing scheduled for March 26, 2026, which stays the delisting pending a final decision, though the company cautioned there is no assurance it will be granted continued listing or regain compliance with Nasdaq requirements.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lunai Bioworks Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on February 23, 2026, and is solely responsibl","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260223:nNDLbGHq3b:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LNAI"],"gpt_icon":0},{"id":"2612400747","title":"Lunai Bioworks Secures U.S. Patent for AI Debiasing Framework in Drug Discovery","url":"https://stock-news.laohu8.com/highlight/detail?id=2612400747","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612400747?lang=en_us&edition=fundamental","pubTime":"2026-02-19 21:32","pubTimestamp":1771507939,"startTime":"0","endTime":"0","summary":"Lunai Bioworks Inc. announced the issuance of U.S. Patent No. 12,369,861, titled “Methods, Systems, and Frameworks for Debiasing Data in Drug Discovery Predictions.” The patent covers multimodal data standardization and structural bias removal prior to predictive modeling, aimed at improving confidence in biomarker discovery, disease stratification, and gene network mapping.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260219:nNDLFL072:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LNAI"],"gpt_icon":0},{"id":"2612953624","title":"Lunai Bioworks Inc. - Common Stock Q2 EPS $(0.08) Up From $(0.45) YoY","url":"https://stock-news.laohu8.com/highlight/detail?id=2612953624","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612953624?lang=en_us&edition=fundamental","pubTime":"2026-02-18 06:03","pubTimestamp":1771365837,"startTime":"0","endTime":"0","summary":"Lunai Bioworks Inc. - Common Stock (NASDAQ:LNAI) reported quarterly losses of $(0.08) per share. This is a 82.22 percent increase over losses of $(0.45) per share from the same period last year.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/02/50674117/lunai-bioworks-inc-common-stock-q2-eps-0-08-up-from-0-45-yoy","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Lunai Bioworks Inc. - Common Stock Q2 EPS $(0.08) Up From $(0.45) YoY","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LNAI"],"gpt_icon":0},{"id":"2612946206","title":"Lunai Bioworks net income loss narrows to USD 1.80 million in Q4, down 75 percent","url":"https://stock-news.laohu8.com/highlight/detail?id=2612946206","media":"Reuters","labels":["dataReport","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612946206?lang=en_us&edition=fundamental","pubTime":"2026-02-18 04:17","pubTimestamp":1771359446,"startTime":"0","endTime":"0","summary":"Lunai Bioworks Inc. reported its results for the quarter ending December 31, 2025. The company ended the period with cash and cash equivalents of USD 0.49 million and an accumulated deficit of USD 509.44 million, with a working capital deficit of USD 19.49 million. Management highlighted that there is substantial doubt about Lunai Bioworks’ ability to continue as a going concern due to recurring losses and reliance on additional financing. During the period, Lunai Bioworks completed the acquisition of BioSymetrics Inc. and its subsidiary on April 8, 2025. Earlier, GediCube, B.V., previously acquired in 2024, filed for bankruptcy and ceased operations. Additionally, the company changed its corporate name from Renovaro Inc. to Lunai Bioworks Inc. on August 20, 2025. Management stated that future funding is expected to support ongoing obligations, product commercialization, clinical and regulatory development, and working capital needs.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260217:nNDL22QZyt:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LNAI","BK4139"],"gpt_icon":0},{"id":"2611774157","title":"Lunai Bioworks CEO Showcases AI Drug Discovery Platform on CNBC","url":"https://stock-news.laohu8.com/highlight/detail?id=2611774157","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611774157?lang=en_us&edition=fundamental","pubTime":"2026-02-13 21:32","pubTimestamp":1770989548,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lunai Bioworks Inc. published the original content used to generate this news brief via PR Newswire  on February 13, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260213:nNDL5bLrLq:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LNAI","BK4139"],"gpt_icon":0},{"id":"2611597025","title":"Nasdaq Moves to Delist Lunai Bioworks for Minimum Bid Price Violation","url":"https://stock-news.laohu8.com/highlight/detail?id=2611597025","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611597025?lang=en_us&edition=fundamental","pubTime":"2026-02-13 05:17","pubTimestamp":1770931075,"startTime":"0","endTime":"0","summary":"Lunai Bioworks Inc. is facing potential delisting from the Nasdaq Capital Market after receiving notice from Nasdaq that the company is not in compliance with the minimum bid price requirement of $1.00 per share, as outlined in Nasdaq Listing Rule 5550. The company's stock traded below this threshold for 30 consecutive business days, triggering the notice. Due to a 1-for-10 reverse stock split conducted within the past year, Lunai Bioworks is not eligible for a standard 180-day compliance period. The company has requested a hearing to appeal the delisting determination, which temporarily stays the suspension of its securities pending the outcome. If the appeal is unsuccessful or not filed by the deadline, Lunai Bioworks’ shares will be suspended from trading and officially delisted.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260212:nNDL15cqnQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LNAI"],"gpt_icon":0},{"id":"2610629968","title":"Lunai Bioworks Unveils AI Platform Targeting Disease Subtypes for Precision Drug Discovery","url":"https://stock-news.laohu8.com/highlight/detail?id=2610629968","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610629968?lang=en_us&edition=fundamental","pubTime":"2026-02-10 22:52","pubTimestamp":1770735173,"startTime":"0","endTime":"0","summary":"Lunai Bioworks Inc. has released a presentation detailing its approach to drug discovery and development. The company highlights its proprietary Augusta platform, which utilizes artificial intelligence to analyze clinical-grade patient data and identify biologically distinct subtypes within complex diseases. This process enables the design and early validation of precision-matched therapies in living systems, aiming to reduce clinical failure risk, accelerate development timelines, and improve capital efficiency. The presentation also addresses industry challenges such as rising development costs, lengthy timelines, and the impact of patent expirations on pharmaceutical revenues. You can access the full presentation through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be int","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260210:nNDLP7V05:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LNAI"],"gpt_icon":0},{"id":"2610569056","title":"Lunai Bioworks startet KI-Onkologie-Pilotprojekt mit klinischem Partner","url":"https://stock-news.laohu8.com/highlight/detail?id=2610569056","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610569056?lang=en_us&edition=fundamental","pubTime":"2026-02-09 22:15","pubTimestamp":1770646532,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lunai Bioworks Inc. published the original content used to generate this news brief via PR Newswire  on February 09, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260209:nNDL8zW65r:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LNAI","BK4139"],"gpt_icon":0},{"id":"2610656973","title":"Lunai Bioworks (Nasdaq: Lnai) Launches AI Oncology Pilot With Clinical-Stage Partner to Analyze Randomized Phase 2 Metastatic Colorectal Cancer Survival Trial Data","url":"https://stock-news.laohu8.com/highlight/detail?id=2610656973","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610656973?lang=en_us&edition=fundamental","pubTime":"2026-02-09 22:15","pubTimestamp":1770646500,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260209:nTUA5V13JD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","LNAI"],"gpt_icon":0},{"id":"2606356377","title":"Lunai Bioworks Unveils AI Tool to Block Novel Chemical Weapon Designs","url":"https://stock-news.laohu8.com/highlight/detail?id=2606356377","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606356377?lang=en_us&edition=fundamental","pubTime":"2026-01-27 23:37","pubTimestamp":1769528265,"startTime":"0","endTime":"0","summary":"Lunai Bioworks Inc. has announced the deployment of Sentinel, a transformer-based AI safeguard designed to prevent large language models from generating novel chemical weapons. Built on Lunai's proprietary toxicology and in-vivo datasets, Sentinel embeds directly into scientific AI systems to detect and halt the creation of previously unknown threat agents in real time. The company positions Sentinel as a critical biosecurity layer amid growing concerns about the misuse of advanced AI in chemistry and biology. These results have already been announced by Lunai Bioworks.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lunai Bioworks Inc. published the original content used to generate this news brief via PR Newswire  on January 27, 2026,","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260127:nNDL8YJBtr:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LNAI","BK4139"],"gpt_icon":0},{"id":"2606246445","title":"Lunai Bioworks Secures NIH Grant for Alcohol Use Disorder Drug Discovery Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2606246445","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606246445?lang=en_us&edition=fundamental","pubTime":"2026-01-26 22:30","pubTimestamp":1769437825,"startTime":"0","endTime":"0","summary":"Lunai Bioworks Inc.  has received a Small Business Technology Transfer  grant from the National Institutes of Health  to support its new commercial drug discovery program targeting Alcohol Use Disorder . The program is conducted in collaboration with Dr. Calum MacRae, Vice Chair, Scientific Innovation at Brigham and Women's Hospital and Professor of Medicine at Harvard Medical School. The initiative aims to develop mechanism-informed therapeutic candidates for AUD, leveraging Lunai’s AI-powered platform and high-throughput vertebrate screening infrastructure.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lunai Bioworks Inc. published the original content used to generate this news brief via PR Newswire  on January 26, 2026, and is sol","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260126:nNDL2GS69k:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LNAI"],"gpt_icon":0},{"id":"2603637043","title":"Lunai Bioworks Unveils AI-Driven Platform to De-Risk Drug Discovery in Complex Diseases","url":"https://stock-news.laohu8.com/highlight/detail?id=2603637043","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603637043?lang=en_us&edition=fundamental","pubTime":"2026-01-14 04:17","pubTimestamp":1768335458,"startTime":"0","endTime":"0","summary":"Lunai Bioworks Inc. has released a presentation detailing its approach to drug discovery using advanced artificial intelligence. The company’s Augusta platform applies AI to analyze patient populations with complex neurological disorders, integrating high-dimensional human data to identify biologically distinct sub-diseases and match them with the most promising therapies. By validating drug candidates in living systems, Lunai aims to deliver de-risked therapeutics, reduce failure rates, and accelerate development timelines for pharmaceutical partners. The presentation highlights the shift in biopharma strategy toward “biology-first” AI platforms that focus on understanding disease mechanisms and improving patient stratification, particularly in the context of major neurological conditions such as Parkinson’s disease, epilepsy, and mental health disorders. You can access the full presentation through the link below.Disclaimer: This news brief was created by Public Technologies  using g","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260113:nNDL2YHkBp:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LNAI"],"gpt_icon":0},{"id":"2590346916","title":"Lunai Bioworks Inc - Identifies Three Parkinson's Disease Subtypes","url":"https://stock-news.laohu8.com/highlight/detail?id=2590346916","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590346916?lang=en_us&edition=fundamental","pubTime":"2025-12-09 20:45","pubTimestamp":1765284336,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251209:nFWN3XF0HG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LNAI","BK4139"],"gpt_icon":0},{"id":"2590346910","title":"Lunai Bioworks Inc - Prioritized Drug Targets in $13 Bln Parkinson's Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2590346910","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590346910?lang=en_us&edition=fundamental","pubTime":"2025-12-09 20:45","pubTimestamp":1765284336,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251209:nFWN3XF0HG:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","LNAI"],"gpt_icon":0},{"id":"2590634696","title":"Lunai Bioworks Identifies Three Parkinson's Subtypes and Prioritizes Drug Targets","url":"https://stock-news.laohu8.com/highlight/detail?id=2590634696","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590634696?lang=en_us&edition=fundamental","pubTime":"2025-12-09 20:45","pubTimestamp":1765284322,"startTime":"0","endTime":"0","summary":"Lunai Bioworks Inc., an AI-powered biotechnology company, has announced the identification of three clinically relevant subtypes of Parkinson's disease and prioritized drug targets using its proprietary Augusta Platform. By integrating large-scale proteomic data from the Parkinson's Progression Markers Initiative with detailed clinical phenotyping, the company uncovered subtypes associated with rapid progression, cognitive decline, and functional impairment. These findings, recently highlighted in Science Times, aim to support the development of precision therapies and accelerate proof-of-concept programs. Lunai Bioworks is also exploring partnerships to apply these insights to ongoing drug development, co-develop biomarkers and companion diagnostics, and design smarter clinical trials.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for i","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251209:nNDLb1yhHv:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LNAI"],"gpt_icon":0},{"id":"2588046695","title":"BRIEF-Lunai Bioworks - Enters Sales Agreement With Dawson James Securities - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2588046695","media":"Reuters","labels":["corporation","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588046695?lang=en_us&edition=fundamental","pubTime":"2025-12-03 20:49","pubTimestamp":1764766172,"startTime":"0","endTime":"0","summary":"BRIEF-Lunai Bioworks - Enters Sales Agreement With Dawson James Securities - SEC FilingDec 3  - Lunai Bioworks Inc LNAI.O:LUNAI BIOWORKS INC - ENTERS SALES AGREEMENT WITH DAWSON JAMES SECURITIES - SEC FILINGLUNAI BIOWORKS INC - MAY OFFER & SELL STOCK UP TO $11.70 MILLION - SEC FILINGSource text: [ID:n0001731122-25-001625]Further company coverage: LNAI.O ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251203:nFWN3X815K:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LNAI","BK4139"],"gpt_icon":0},{"id":"2588100250","title":"Lunai Bioworks Inc - May Offer & Sell Stock up to $11.70 Mln - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2588100250","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588100250?lang=en_us&edition=fundamental","pubTime":"2025-12-03 19:06","pubTimestamp":1764759993,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251203:nFWN3X815K:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LNAI","BK4139"],"gpt_icon":0},{"id":"2586401146","title":"Lunai Bioworks Raises $3.1 Million in Private Placement of Shares and Warrants","url":"https://stock-news.laohu8.com/highlight/detail?id=2586401146","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586401146?lang=en_us&edition=fundamental","pubTime":"2025-11-26 05:49","pubTimestamp":1764107399,"startTime":"0","endTime":"0","summary":"Lunai Bioworks Inc. has announced a private placement with an accredited investor, selling 3,133,333 shares of its common stock at $1.00 per share, raising gross proceeds of $3,133,333. The agreement also includes the issuance of 1,044,444 three-year warrants, exercisable after 60 days. The securities were offered in reliance on exemptions from registration under the Securities Act, and are subject to resale restrictions. No underwriting discounts or commissions were paid in connection with the transaction.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lunai Bioworks Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securit","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251125:nNDL8q3QLd:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LNAI","BK4139"],"gpt_icon":0},{"id":"2586478744","title":"Lunai Bioworks Secures First Licensing LOI for Immune Cell Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2586478744","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586478744?lang=en_us&edition=fundamental","pubTime":"2025-11-25 20:45","pubTimestamp":1764074718,"startTime":"0","endTime":"0","summary":"Lunai Bioworks Inc. announced it has secured its first Letter of Intent  to license its next-generation immune cell therapy platform. The agreement follows recent peer-reviewed publication of preclinical data showing complete regression of primary and metastatic pancreatic tumors in humanized models, with no recurrence observed. The company plans to advance the platform, known as Dendritic Cell Combination Therapy , toward scalable clinical applications for aggressive cancers.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lunai Bioworks Inc. published the original content used to generate this news brief via PR Newswire  on November 25, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251125:nNDL9RRxcL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LNAI"],"gpt_icon":0},{"id":"2586478712","title":"Lunai Bioworks Secures First Licensing Loi Following Landmark Breakthrough Showing Complete Tumor Regression in Humanized Cancer Models","url":"https://stock-news.laohu8.com/highlight/detail?id=2586478712","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586478712?lang=en_us&edition=fundamental","pubTime":"2025-11-25 20:45","pubTimestamp":1764074700,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251125:nTUA7GVW6G:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","LNAI"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":35,"code":"91000000","status":"200"}]}}